|
1
|
Zhang H, Yang T, Wu M and Shen F:
Intrahepatic cholangiocarcinoma: Epidemiology, risk factors,
diagnosis and surgical management. Cancer Lett. 379:198–205.
2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Doherty B, Nambudiri VE and Palmer WC:
Update on the diagnosis and treatment of cholangiocarcinoma. Curr
Gastroenterol Rep. 19(2)2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Blechacz B and Gores GJ:
Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and
treatment. Hepatology. 48:308–321. 2008.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Yugawa K, Itoh S, Kurihara T, Yoshiya S,
Mano Y, Takeishi K, Harada N, Ikegami T, Soejima Y, Mori M and
Yoshizumi T: Skeletal muscle mass predicts the prognosis of
patients with intrahepatic cholangiocarcinoma. Am J Surg.
218:952–958. 2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Sakamoto Y, Kokudo N, Matsuyama Y,
Sakamoto M, Izumi N, Kadoya M, Kaneko S, Ku Y, Kudo M, Takayama T,
et al: Proposal of a new staging system for intrahepatic
cholangiocarcinoma: Analysis of surgical patients from a nationwide
survey of the liver cancer study group of Japan. Cancer. 122:61–70.
2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Fadok VA, Bratton DL, Rose DM, Pearson A,
Ezekewitz RA and Henson PM: . A receptor for
phosphatidylserine-specific clearance of apoptotic cells. Nature.
405:85–90. 2000.PubMed/NCBI View
Article : Google Scholar
|
|
7
|
Chang B, Chen Y, Zhao Y and Bruick RK:
JMJD6 is a histone arginine demethylase. Science. 318:444–447.
2007.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Unoki M, Masuda A, Dohmae N, Arita K,
Yoshimatsu M, Iwai Y, Fukui Y, Ueda K, Hamamoto R, Shirakawa M, et
al: Lysyl 5-hydroxylation, a novel histone modification, by Jumonji
domain containing 6 (JMJD6). J Biol Chem. 288:6053–6062.
2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Yang J, Chen S, Yang Y, Ma X, Shao B, Yang
S, Wei Y and Wei X: Jumonji domain-containing protein 6 protein and
its role in cancer. Cell Prolif. 53(e12747)2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Nolz JC: Molecular mechanisms of CD8(+) T
cell trafficking and localization. Cell Mol Life Sci. 72:2461–2473.
2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Farhood B, Najafi M and Mortezaee K:
CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A
review. J Cell Physiol. 234:8509–8521. 2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Yugawa K, Itoh S, Yoshizumi T, Iseda N,
Tomiyama T, Toshima T, Harada N, Kohashi K, Oda Y and Mori M:
Prognostic impact of tumor microvessels in intrahepatic
cholangiocarcinoma: Association with tumor-infiltrating
lymphocytes. Mod Pathol. 34:798–807. 2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Asahi Y, Hatanaka KC, Hatanaka Y, Kamiyama
T, Orimo T, Shimada S, Nagatsu A, Sakamoto Y, Kamachi H, Kobayashi
N, et al: Prognostic impact of CD8+ T cell distribution
and its association with the HLA class I expression in intrahepatic
cholangiocarcinoma. Surg Today. 50:931–940. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ronnekleiv-Kelly SM and Pawlik TM: Staging
of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr.
6:35–43. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Fontugne J, Augustin J, Pujals A,
Compagnon P, Rousseau B, Luciani A, Tournigand C, Cherqui D,
Azoulay D, Pawlotsky JM and Calderaro J: PD-L1 expression in
perihilar and intrahepatic cholangiocarcinoma. Oncotarget.
8:24644–24651. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Yugawa K, Itoh S, Yoshizumi T, Iseda N,
Tomiyama T, Morinaga A, Toshima T, Harada N, Kohashi K, Oda Y and
Mori M: CMTM6 stabilizes PD-L1 expression and is a new prognostic
impact factor in hepatocellular carcinoma. Hepatol Commun.
5:334–348. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Berardo C, Siciliano V, Di Pasqua LG,
Richelmi P, Vairetti M and Ferrigno A: Comparison between
Lipofectamine RNAiMAX and GenMute transfection agents in two
cellular models of human hepatoma. Eur J Histochem.
63(3048)2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Izumi T, Sakata K, Okuzaki D, Inokuchi S,
Tamura T, Motooka D, Nakamura S, Ono C, Shimokawa M, Matsuura Y, et
al: Characterization of human pegivirus infection in liver
transplantation recipients. J Med Virol. 91:2093–2100.
2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Shimokawa M, Yoshizumi T, Itoh S, Iseda N,
Sakata K, Yugawa K, Toshima T, Harada N, Ikegami T and Mori M:
Modulation of Nqo1 activity intercepts anoikis resistance and
reduces metastatic potential of hepatocellular carcinoma. Cancer
Sci. 111:1228–1240. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Feng M, Pan Y, Kong R and Shu S: Therapy
of primary liver cancer. Innovation (Camb).
1(100032)2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Sheng W, LaFleur MW, Nguyen TH, Chen S,
Chakravarthy A, Conway JR, Li Y, Chen H, Yang H, Hsu PH, et al:
LSD1 ablation stimulates anti-tumor immunity and enables checkpoint
blockade. Cell. 174:549–563.e19. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wan J, Liu H, Yang L, Ma L, Liu J and Ming
L: JMJD6 promotes hepatocellular carcinoma carcinogenesis by
targeting CDK4. Int J Cancer. 144:2489–2500. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wong M, Sun Y, Xi Z, Milazzo G, Poulos RC,
Bartenhagen C, Bell JL, Mayoh C, Ho N, Tee AE, et al: JMJD6 is a
tumorigenic factor and therapeutic target in neuroblastoma. Nat
Commun. 10(3319)2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wang F, He L, Huangyang P, Liang J, Si W,
Yan R, Han X, Liu S, Gui B, Li W, et al: JMJD6 promotes colon
carcinogenesis through negative regulation of p53 by hydroxylation.
PLoS Biol. 12(e1001819)2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Itoh S, Yoshizumi T, Yugawa K, Imai D,
Yoshiya S, Takeishi K, Toshima T, Harada N, Ikegami T, Soejima Y,
et al: Impact of immune response on outcomes in hepatocellular
carcinoma: Association with vascular formation. Hepatology.
72:1987–1999. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Yugawa K, Itoh S, Iseda N, Kurihara T,
Kitamura Y, Toshima T, Harada N, Kohashi K, Baba S, Ishigami K, et
al: Obesity is a risk factor for intrahepatic cholangiocarcinoma
progression associated with alterations of metabolic activity and
immune status. Sci Rep. 11(5845)2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ikeda S, Okamoto T, Okano S, Umemoto Y,
Tagawa T, Morodomi Y, Kohno M, Shimamatsu S, Kitahara H, Suzuki Y,
et al: PD-L1 is upregulated by simultaneous amplification of the
PD-L1 and JAK2 genes in non-small cell lung cancer. J Thorac Oncol.
11:62–71. 2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Lu C, Paschall AV, Shi H, Savage N, Waller
JL, Sabbatini ME, Oberlies NH, Pearce C and Liu K: The MLL1-H3K4me3
axis-mediated PD-L1 expression and pancreatic cancer immune
evasion. J Natl Cancer Inst. 109(djw283)2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Gong J, Chehrazi-Raffle A, Reddi S and
Salgia R: Development of PD-1 and PD-L1 inhibitors as a form of
cancer immunotherapy: A comprehensive review of registration trials
and future considerations. J Immunother Cancer. 6(8)2018.PubMed/NCBI View Article : Google Scholar
|
